Safety of medical male circumcision in human immunodeficiency virus-infected men in Rakai, Uganda

Godfrey Kigozi, Richard Musoke, Nehemiah Kighoma, Noah Kiwanuka, Fred Makumbi, Fred Nalugoda, Fred Wabwire-Mangen, David Serwadda, Maria Joan Wawer, Ronald Henry Gray

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Objective To assess the safety of medical male circumcision (MMC) among human immunodeficiency virus (HIV)-infected men with CD4 levels <350 cells/mm3, CD4 counts ≥350 cells/mm3, and HIV-negative men. Methods Two hundred forty-two HIV-infected men and a sample of 262 HIV-negative consenting men aged 12 years or older who requested free MMC were enrolled in a prospective study. Blood for HIV testing and a CD4 count were collected before surgery. During weekly follow-up over 6 weeks, data were collected on wound healing and adverse events (AEs) by examination, and resumption of sex and condom use ascertained by interview. Surgery-related AEs were characterized by type, severity, management, and resolution. Chi-square and Fisher's exact tests were used to test for differences in AE proportions. Results Overall, only 2 of the 453 men experienced moderate AEs, a rate of 0.44 per 100 surgeries. No AE occurred among HIV-negative men, whereas the AE rate among HIV-infected men with CD4 counts ≥350 cells/mm3 was 0.79 per 100 surgeries, and among men with CD4 counts <350 cells/mm3 the rate was 1.19 per 100 surgeries (P =.214). AE rates were comparable for all characteristics (P >.05). Conclusion HIV-positive men can be safely included in MMC roll out programs without necessitating presurgery CD4 counts determination.

Original languageEnglish (US)
Pages (from-to)294-297
Number of pages4
Issue number2
StatePublished - Feb 2014

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Safety of medical male circumcision in human immunodeficiency virus-infected men in Rakai, Uganda'. Together they form a unique fingerprint.

Cite this